The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC 50 values), and IC 90 values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.
Infections caused by Candida glabrata have been reported to be increasing in frequency (19, 30) and are associated with high mortality rates for the elderly, immunocompromised patients, and patients in intensive care units (2, 11, 27) . Treatment may be complicated by the variable susceptibility of C. glabrata to fluconazole and by reduced response rates to other azole antifungals in breakthrough infections (2, 11, 22, 26, 29) .
The echinocandins have emerged as an effective treatment strategy for invasive candidiasis. Although susceptibility breakpoints are not currently established, broth microdilution studies have demonstrated relatively good activity for each member of this class against Candida isolates, including non-C. albicans species (13, 28) . However, case reports describing clinical failures of caspofungin associated with reduced in vitro activity against C. albicans, C. glabrata, and C. krusei have begun to emerge (6, 7, 9, 10, 14, 21 Microdilution broth susceptibility testing was performed in duplicate according to the CLSI M27-A2 method in RPMI growth medium buffered with 0.165 M 4-morpholinepropanesulfonic acid (15) . The MIC 2 was defined as the lowest concentration of anidulafungin or caspofungin that caused a significant decrease in turbidity (Ն50%) compared to that of the growth control, and the MIC 0 was defined as the lowest concentration resulting in no visual growth. The minimum fungicidal concentration (MFC) was measured as previously described (5).
The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) colorimetric assay was performed in triplicate as previously reported (12) . Final anidulafungin concentrations ranged from 0.015 to 32 g/ml, and those of caspofungin ranged from 0.06 to 128 g/ml. The absorbance was read at 492 nm, and readings were converted to percent absorbance, with values for growth control wells set at 100% and those for medium control wells set at 0%. XTT reduction assay data were fit to a four-parameter inhibitory sigmoid model, using computer curve fitting software (Prism 4; GraphPad Software, Inc., San Diego, CA), to derive 50% inhibitory concentration (IC 50 ) and IC 90 values. The goodness of fit for each isolate/drug was assessed by the R 2 value and the standard error of the IC 50 value. The IC 50 and IC 90 values were not determined if minimal or no reduction in formazan absorbance was observed with increasing drug concentrations.
Time-kill studies were performed in duplicate on isolates with caspofungin MICs of Ն8 g/ml, using previously described methods (8) . The anidulafungin and caspofungin concentrations tested were 0.5, 1.0, 4.0, 8.0, and 16 g/ml. These are within the range achieved clinically for both agents (3, 4, 25) . Fungicidal activity was defined as a Ն3-log 10 (99.9%) reduction in CFU from the starting inoculum.
Anidulafungin MICs ranged from 0.125 to 4 g/ml and were at least two dilutions lower than those of caspofungin (range, 1 to 64 g/ml) for 16 of the 18 isolates tested, including the three isolates with elevated caspofungin MICs (Table 1) . Similarly, the MFCs for anidulafungin (range, 0.25 to 8 g/ml) were Ն2 dilutions lower than those of caspofungin (1 to Ն128 g/ml) for 14 of the 18 isolates tested. Anidulafungin remained fungicidal against the three strains with elevated caspofungin MFCs (Ն64 g/ml).
The potency of anidulafungin was greater than that of caspofungin, as evidenced by a lower IC 50 value for each strain evaluated (Table 1) . Similarly, the IC 90 values for anidulafungin were also lower than those for caspofungin against all isolates. Against the isolates with caspofungin MICs of Ն8 g/ml, only the highest concentration of caspofungin tested (128 g/ml) resulted in a Ͼ90% reduction in viability, while anidulafungin maintained its potency (IC 50 range, 0.17 to 2.4 g/ml; IC 90 range, 3.6 to 7.8 g/ml).
These results are supported by data from time-kill studies (Fig. 1) . Against C. glabrata isolate 16, anidulafungin at 1 g/ml resulted in a Ͼ3-log 10 CFU/ml decrease in the starting inoculum at 24 h, compared to a 0.43-log 10 CFU/ml reduction for caspofungin at 16 g/ml. Anidulafungin at 4 g/ml was fungicidal against isolate 18, in contrast to the 0.54-log 10 CFU/ml increase observed with caspofungin at 16 g/ml. Minimal activity was also observed for caspofungin against C. glabrata isolate 17 at the highest concentration tested (0.65-log 10 increase in CFU/ml at 16 g/ml). Although anidulafungin was not fungicidal against this isolate, concentrations of Ն4 g/ml did result in reductions in colony counts (Ն1.74-log 10 CFU/ml decrease).
Surveillance studies have reported relatively good activities Curves were generated by fitting XTT data to a four-parameter inhibitory sigmoid model. Symbols in time-kill plots (B, C, E, F, H, and I) show the mean values for log 10 CFU/ml versus time for anidulafungin (B, E, and H) and caspofungin (C, F, and I) against C. glabrata isolates with caspofungin MICs of Ն8 g/ml. Drug concentrations: ■, control; OE, 0.5 g/ml; }, 1 g/ml; F, 4 g/ml; , 8 g/ml; and *, 16 g/ml. Symbols represent the means Ϯ standard errors for experiments performed in duplicate for each drug. E max values represent maximum log 10 reductions in CFU/ml for anidulafungin and caspofungin against each isolate at 24 h. VOL. 50, 2006 NOTES 3927 for the echinocandins compared to other antifungals against Candida species, including non-C. albicans and fluconazoleresistant isolates (1, 5, 16, 17, 24) . Against the isolates of C. glabrata tested for this study, anidulafungin had greater in vitro potency than did caspofungin, as evidenced by lower MIC and MFC values. The enhanced potency of anidulafungin against C. glabrata isolates is also supported by pharmacodynamic data from XTT and time-kill assays and was maintained against C. glabrata isolates with elevated caspofungin MICs. While no strong correlation exists between susceptibility data and clinical success in the treatment of invasive fungal infections, in vitro and in vivo data suggest that antifungal MICs may be predictive of responses to therapy (7, 9) . Furthermore, antifungal resistance is associated with clinical failure (9, 18, 20, 23) . Recent reports suggested that this may also be true for caspofungin in the setting of elevated MICs (6, 7, 9, 10, 14, 21) . Due to the difficulty in treating invasive candidiasis that is unresponsive to prior therapy, further studies investigating the utility of anidulafungin in this setting are warranted.
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